January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline Four Icon Pipeline Four Header 

Cambridge Healthtech Institute’s 18th Annual
Recombinant Protein Expression
Achieving Quality and Quantity
January 19-20, 2016

Biopharmaceuticals currently represent the fastest-growing sector of the pharmaceutical industry, driven by a rapid expansion in the manufacture of recombinant protein-based drugs. To meet the demand, it is crucial to increase the throughput of expression, production and purification processes and systems.

Cambridge Healthtech Institute’s Recombinant Protein Expression conference explores the newest data and innovations relating to the best choices in hosts / systems, as well as ways to “rescue” existing systems and make them work more effectively to produce the quality and quantity of the desired biotherapeutic.

Preliminary Agenda 


Production of Human Lysosomal Enzymes in Microorganism: Achievements and Challenges

Carlos J. Alméciga-Díaz, Ph.D., BPharm, Associate Professor, Institute for the Study of Inborn Errors of Metabolism (IEIM), School of Sciences, Pontificia Universidad Javeriana

High-Titer Production of Knob-into-Hole Bispecific Antibodies in E. coli 

James Giulianotti, Senior Research Associate, Early Stage Cell Culture, Genentech, Inc.

Production of Complex Protein Therapeutics in the Chloroplast of the Green Algae Chlamydomonas reinhardtii 

Melissa Scranton, Ph.D., Researcher, Stephen Mayfield Laboratory, Food & Fuel for the 21st Century, University of California, San Diego


Light-Controlled Intracellular Delivery of Native Peptides and Proteins

Norbert O. Reich, Ph.D., Professor, Chemistry & Biochemistry, University of California, Santa Barbara

Cell-Free Expression of High-Quality GPCRs in Eukaryotic and Prokaryotic Lysates

Ralf-Bernhardt Rues, Research Fellow, Institute of Biophysical Chemistry, Goethe University Frankfurt

Membrane Proteins: From Lab-Scale toward Large-Scale Production

Julie Bomholt, Ph.D., Protein Specialist, Research and Development, Aquaporin A/S

Expression of Membrane Recombinant Hemagglutinins, Components of Influenza Vaccine Flublok®, Using Baculovirus Expression System

Nikolai Khramtsov, Ph.D., Associate Director, Upstream Development, Process Development, Protein Sciences Corp.


Exploiting the Proteomics Revolution in Biotechnology: From Disease and Antibody Targets to Optimizing Bioprocess Development

Deniz Baycin-Hizal, Ph.D., Scientist I, MedImmune

Multi-Omics Approach for Comparative Studies of Monoclonal Antibody-Producing CHO Cells

Lars Keld Nielsen, Ph.D., Chair & Professor, Biological Engineering, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland

Designing CHO Cell Factories Using System Biology Models

Nathan E. Lewis, Ph.D., Assistant Professor, Department of Pediatrics, University of California, San Diego

Speed-to-Clinic Cell Line Development without Compromising on Cell Line Stability

Gang Chen, Ph.D., Executive Director, Protein Expression Sciences, Regeneron Pharmaceuticals, Inc.

PhyNexusPresentation to be Anounced

SelexisSelexis SUREcode™: De-risking Research Cell Bank Generation with Comprehensive Genomic Analysis

Pierre-Alain Girod, Ph.D., CSO, Selexis

For questions about the meeting, please contact: 

Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5497
Email: mabrown@healthtech.com 

For partnering & sponsorship information, please contact: 

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com 

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com